CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Amgen
Beijing Biotech
Bristol-Myers Squibb
Daiichi Sankyo
Servier
AstraZeneca
Sumitomo Pharma America, Inc.
Curis, Inc.
Radboud University Medical Center
Sellas Life Sciences Group
Allogene Therapeutics
Dana-Farber Cancer Institute
SymBio Pharmaceuticals
BIOHENG THERAPEUTICS US LLC
Incyte Corporation
Genmab
Memorial Sloan Kettering Cancer Center
Bambino Gesù Hospital and Research Institute
St. Jude Children's Research Hospital
Advesya SAS
BlueSphere Bio, Inc
Biotroy Therapeutics
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Aptose Biosciences Inc.
AbbVie
Goethe University
Jonsson Comprehensive Cancer Center
Shanghai EpimAb Biotherapeutics Co., Ltd.
M.D. Anderson Cancer Center
Affiliated Hospital to Academy of Military Medical Sciences
AbbVie
Essen Biotech
The First Affiliated Hospital of Soochow University
Mustang Bio
MingSight Pharmaceuticals, Inc
Altor BioScience
Princess Maxima Center for Pediatric Oncology
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Novartis
M.D. Anderson Cancer Center
Kartos Therapeutics, Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Assistance Publique - Hôpitaux de Paris
University Health Network, Toronto
Sumitomo Pharma America, Inc.